Amgen Inc. Chairman and CEOacknowledges the company's move to a new R&D site in South San Francisco isn't a big deal — at least as far as geography — but as far as culture, recruitment, retention and the chance to deliver scientifically, it's huge.
That much hasn't changed as the company moves from four buildings with three stories each totaling 348,000 square feet on Veterans Boulevard to the single, nine-story, 240,000-square-foot structure at 750 Gateway Blvd. — less than a 10-minute walk between the two sites. But Bradway said the biggest change will come as Amgen unites about 600 employees and contractors under one roof, attracts the best talent and takes advantage of"commingling" discoveries.
Meanwhile, Amgen and South San Francisco continue to grow. The company is in the process of buying of ChemoCentryx Inc. of San Carlos for $3.7 billion and last year acquired Teneobio Inc. of Newark and Five Prime Therapeutics Inc., which was just across Oyster Point Boulevard., the company's vice president of research and local site head. Planning for the move started at least two years ago, but executing on those plans started only in the second quarter, he said.
"The magic happens when you allow people to flow seamlessly, laterally or up-and-down. People bump into each other in their neighborhoods," Haldar said.Haldar also pointed out the building's conference space, where he was giving a presentation to Bradway and employees Thursday afternoon, a fitness center with a spa and Gateway of Pacific amenities, including a building with a coffee shop.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: SFBusinessTimes - 🏆 78. / 68 Lire la suite »
La source: SFBusinessTimes - 🏆 78. / 68 Lire la suite »
La source: SFBusinessTimes - 🏆 78. / 68 Lire la suite »